Comparative study reveals differences in neutrophil elastase production in COPD exacerbators, suggesting insights for treatment.
Introduction Neutrophilic inflammation, particularly from proteinases such as neutrophil elastase is implicated in the pathogenesis of COPD (Thorax 2006; 61: 250). We compared unstimulated and stimulated production of neutrophil elastase in people suffering >2 exacerbations, needing oral steroids or hospital attendance in the last 12 months and those having no exacerbations. Methods Subjects: people with COPD (Stage 3-4), prescribed optimal medical therapy and all ex-smokers (eCO<10ppm). Unstimulated and stimulated (bacterial lipopolysaccharide; 840-15, Sigma, UK) neutrophil-specific elastase production was determined with a commercially available enzyme-linked immunosorbent assay (Merck, Germany) from plasma and spontaneous sputum. Results Clinical characteristics and neutrophil-specific elastase concentrations Frequent exacerbators (N = 36) Non-exacerbators (N = 20) p-value Age (years) 66 ± 8 70 ± 8 0.16 FEV1% predicted 44 ± 17 43 ± 17 0.89 Unstimulated plasma elastase μg/L 433 ± 643 695 ± 854 0.09 Stimulated plasma elastase μg/L 2674 ± 1465 3452 ± 2462 0.37 Unstimulated sputum elastase μg/L 21 ± 31 66 ± 107 0.08 Stimulated sputum elastase μg/L 37 ± 43 13 ± 32 0.02 Data presented as mean ± standard deviation Conclusion Frequent exacerbators have heightened elastase release in response to bacterial stimulation in sputa and a tendency for lower neutrophil-specific elastase concentration at rest in both plasma and sputa compared to non-exacerbators.
No takes yet. Share an insight, caveat, or question.
Jones et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: